drug prices

Most Read

U.S. Sen. Kamala Harris

Politics By Lev Facher

Kamala Harris becomes the latest Democratic candidate to zero in on drug prices

Cognitive dysfunction

Business By Rebecca Robbins

This antidepressant may be no better than cheaper alternatives. But demand could soon soar

Aloquin

Pharmalot By Ed Silverman

The curious case of the $9,500 skin gel

AIDS Healthcare Foundation

Pharmalot By Ed Silverman

Gilead’s new price hikes on HIV drugs anger AIDS activists

Insulin

Pharmalot By Ed Silverman

Insulin prices have skyrocketed, putting drug makers on the defensive

Stark medication bottle

First Opinion By John Arnold

John Arnold: Trump administration’s good effort on drug rebates is bad policy

Jacobus Pharmaceuticals

Pharmalot By Ed Silverman

A family-run drug maker faces tough choices to stay afloat in the Shkreli era

Politics and Pharma illo

Politics By Dylan Scott

Fearing Democratic tidal wave, the drug industry is pouring money into GOP coffers

All Coverage

Compounding Pharmacy

Pharmalot By Ed Silverman

A compounder loses a battle with the FDA over using bulk substances

Wyden Grassley

Politics By Lev Facher and Nicholas Florko

Senate committee unveils ambitious plan to cap drug price hikes, out-of-pocket expenses

advertisement

2018 Senate McCaskill

Politics By Lev Facher

Former pharma hawk McCaskill: Drug pricing system is a ‘stinking stew of a mess’

Pharmalot By Ed Silverman

Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin

Pharmalot By Ed Silverman

Pharmalittle: Roche hits milestone with personalized cancer drug; data on a fountain of youth drug

Pharmacy Benefit Managers

Pharmalot By Ed Silverman

AIDS groups criticize Express Scripts for excluding several HIV medicines

JOHNSON & JOHNSON HEADQUARTERS

Pharmalot By Ed Silverman

Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug

Pharmalot By Ed Silverman

Generic drug price-fixing suit is akin to earlier case, but ‘on steroids,’ Conn. prosecutor says

Antibiotics Pharmacy

Pharmalot By Ed Silverman

Seeking to contain drug costs, CMS may have ‘killed’ a PBM billing practice

Pharmalot By Ed Silverman

Pharmalittle: A Pfizer and Lilly painkiller misses study goals; LA County joins statewide effort to lower drug prices

Eli Lilly insulin

Pharmalot By Ed Silverman

Lilly discloses pricing data on insulin in response to political pressure

Jeffrey Leiden

Pharmalot By Ed Silverman

Vertex CEO says he will bring ‘new ideas’ to break a stalemate in the U.K. over a cystic fibrosis drug

Hep C San Fran

Pharmalot By Ed Silverman

The ‘Netflix’ model for hepatitis C drugs is saving Australia a lot of money

Racial bias Pain Management

Pharmalot By Ed Silverman

Lawmakers ask FDA to explain steps to contain contaminants in blood pressure drugs

Vertex

Pharmalot By Ed Silverman

U.K. lawmaker challenges the government to issue a compulsory license for Vertex drug

Jeffrey Leiden

Pharmalot By Ed Silverman

Vertex faces more pressure over pricing, but one analyst does not expect any movement

Pharmalot By Ed Silverman

Pharmalittle: AstraZeneca chief medical officer is leaving; a venture capital firm bids farewell to J.P. Morgan

Len Schleifer

Pharma By Ed Silverman and Matthew Herper

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

FDA Generic

Pharmalot By Ed Silverman

Canada ends a probe into three big drug makers accused of thwarting generic competition

Drug costs

Pharmalot By Ed Silverman

Trump administration report would preclude reclaiming patents as a way to lower drug prices

Pill illo

Pharmalot By Ed Silverman

As pharma seeks more orphan drug designations, FDA fails to assess important needed info

Pharmalot By Ed Silverman

Pharmalittle: Merck boosts prices on a few drugs; former Insys execs pleads guilty in Subsys conspiracy

Generic epinephrine

Pharmalot By Ed Silverman

FDA promised a ‘lower-cost option’ to EpiPen, but the price isn’t any lower

Pharmalot By Ed Silverman

Pharmalittle: AbbVie sues U.K. over hepatitis C drug program; pharma braces for pricing proposals from Democrats

Humira

Pharmalot By Ed Silverman

AbbVie offers a ‘huge’ discount on Humira to fend off European rivals